Ethics declarations Conflict of interest There is no conflict of interest between the authors or any third party regarding the publication of this article
[DOI] [PMC free article] [PubMed] [Google Scholar] 106.Lee J, Ellis JM, Wolfgang MJ
Sometimes it pools in the tissue and releases erratically over days
Tirzepatide (GLP-1 + GIP): This is a newer, dual-action medication and the same active ingredient as Mounjaro and Zepbound
How they differ Tirzepatide activates two pathways (GLP-1 + GIP) and, on average in studies, produces greater weight loss though individual results vary widely
Furthermore, roughly 60% of participants receiving tirzepatide had achieved normal blood sugar levels after two years, compared to 24% of patients in the control group, according to a report of the study published in Annals of Internal Medicine